ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating Income Operating Income Growth	-156.87	-177.53	-94.31	-74.59	-36.91
Net Income Net Income Growth	-145.24	-166.31	-80.49	-69.33	-36.91
Earnings Per Share EPS Growth	-3.47	-4.32	-2.56	-32.38	-28.90
EPS Growth	-	-	-	-	-

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Investments Cash & Investments Growth	326.38	312.82	218.86	150.39	163.37
Total Debt Total Debt Growth	0.42	0.01	0.18	0.32	0.14
Net Cash (Debt) Net Cash Growth	325.96	312.81	218.69	150.07	163.23
Net Cash Growth	85.27%	43.04%	45.72%	-8.06%	-
Net Cash Per Share Net Cash Per Share Growth	7.91	8.13	6.95	70.10	127.82

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-134.47	-160.59	-70.21	-55.84	-43.63
Free Cash Flow Free Cash Flow Growth	-134.47	-160.59	-70.21	-55.84	-43.63
Free Cash Flow Growth	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.

Data Source: Fiscal.ai Last updated: May 11, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 10, 2026

Data Sources Report a data error